Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philip G Penketh

Showing results (21-30 of 33) with videos related to

Pageof 4
Sort By:
Bioorganic & Medicinal Chemistry Letters|August 31, 2012
Design of a hypoxia-activated prodrug inhibitor of O6-alkylguanine-DNA alkyltransferaseRui Zhu, Helen A Seow, Raymond P Baumann, et al.
Chemical Biology & Drug Design|May 5, 2012
A strategy for selective O(6)-alkylguanine-DNA alkyltransferase depletion under hypoxic conditionsPhilip G Penketh, Krishnamurthy Shyam, Raymond P Baumann, et al.
Journal of Medicinal Chemistry|September 30, 2011
4-nitrobenzyloxycarbonyl derivatives of O(6)-benzylguanine as hypoxia-activated prodrug inhibitors of O(6)-alkylguanine-DNA alkyltransferase (AGT), which produces resistance to agents targeting the O-6 position of DNA guanineRui Zhu, Mao-Chin Liu, Mei-Zhen Luo, et al.
Journal of Medicinal Chemistry|January 23, 2015
Antitumor sulfonylhydrazines: design, structure-activity relationships, resistance mechanisms, and strategies for improving therapeutic utilityKrishnamurthy Shyam, Philip G Penketh, Raymond P Baumann, et al.
Molecular Pharmacology|November 18, 2004
Nuclear localization of NADPH:cytochrome c (P450) reductase enhances the cytotoxicity of mitomycin C to Chinese hamster ovary cellsHelen A Seow, Michael F Belcourt, Philip G Penketh, et al.
Journal of Cancer Therapy|August 16, 2013
Expression of <i>O</i><sup>6</sup>-Methylguanine-DNA Methyltransferase Examined by Alkyl-Transfer Assays, Methylation-Specific PCR and Western Blots in Tumors and Matched Normal TissueKimiko Ishiguro, Krishnamurthy Shyam, Philip G Penketh, et al.
Biochemical Pharmacology|December 26, 2006
Excess ribonucleotide reductase R2 subunits coordinate the S phase checkpoint to facilitate DNA damage repair and recovery from replication stressZ Ping Lin, Michael F Belcourt, Rocco Carbone, et al.
Archives of Toxicology|June 7, 2012
7-Nitro-4-(phenylthio)benzofurazan is a potent generator of superoxide and hydrogen peroxideEric V Patridge, Emma S E Eriksson, Philip G Penketh, et al.
Chemical Biology & Drug Design|July 23, 2011
1,2-Bis(methylsulfonyl)-1-(2-chloroethyl)-2-[[1-(4-nitrophenyl)ethoxy]carbonyl]hydrazine (KS119): a cytotoxic prodrug with two stable conformations differing in biological and physical propertiesPhilip G Penketh, Raymond P Baumann, Krishnamurthy Shyam, et al.
International Journal of Radiation Biology|November 25, 2011
Preclinical evaluation of Laromustine for use in combination with radiation therapy in the treatment of solid tumorsSara Rockwell, Yanfeng Liu, Helen A Seow, et al.
Pageof 4

Showing results (21-30 of 33) with videos related to

Sort By:
Pageof 4
Bioorganic & Medicinal Chemistry Letters|August 31, 2012
Design of a hypoxia-activated prodrug inhibitor of O6-alkylguanine-DNA alkyltransferaseRui Zhu, Helen A Seow, Raymond P Baumann, et al.
Chemical Biology & Drug Design|May 5, 2012
A strategy for selective O(6)-alkylguanine-DNA alkyltransferase depletion under hypoxic conditionsPhilip G Penketh, Krishnamurthy Shyam, Raymond P Baumann, et al.
Journal of Medicinal Chemistry|September 30, 2011
4-nitrobenzyloxycarbonyl derivatives of O(6)-benzylguanine as hypoxia-activated prodrug inhibitors of O(6)-alkylguanine-DNA alkyltransferase (AGT), which produces resistance to agents targeting the O-6 position of DNA guanineRui Zhu, Mao-Chin Liu, Mei-Zhen Luo, et al.
Journal of Medicinal Chemistry|January 23, 2015
Antitumor sulfonylhydrazines: design, structure-activity relationships, resistance mechanisms, and strategies for improving therapeutic utilityKrishnamurthy Shyam, Philip G Penketh, Raymond P Baumann, et al.
Molecular Pharmacology|November 18, 2004
Nuclear localization of NADPH:cytochrome c (P450) reductase enhances the cytotoxicity of mitomycin C to Chinese hamster ovary cellsHelen A Seow, Michael F Belcourt, Philip G Penketh, et al.
Journal of Cancer Therapy|August 16, 2013
Expression of <i>O</i><sup>6</sup>-Methylguanine-DNA Methyltransferase Examined by Alkyl-Transfer Assays, Methylation-Specific PCR and Western Blots in Tumors and Matched Normal TissueKimiko Ishiguro, Krishnamurthy Shyam, Philip G Penketh, et al.
Biochemical Pharmacology|December 26, 2006
Excess ribonucleotide reductase R2 subunits coordinate the S phase checkpoint to facilitate DNA damage repair and recovery from replication stressZ Ping Lin, Michael F Belcourt, Rocco Carbone, et al.
Archives of Toxicology|June 7, 2012
7-Nitro-4-(phenylthio)benzofurazan is a potent generator of superoxide and hydrogen peroxideEric V Patridge, Emma S E Eriksson, Philip G Penketh, et al.
Chemical Biology & Drug Design|July 23, 2011
1,2-Bis(methylsulfonyl)-1-(2-chloroethyl)-2-[[1-(4-nitrophenyl)ethoxy]carbonyl]hydrazine (KS119): a cytotoxic prodrug with two stable conformations differing in biological and physical propertiesPhilip G Penketh, Raymond P Baumann, Krishnamurthy Shyam, et al.
International Journal of Radiation Biology|November 25, 2011
Preclinical evaluation of Laromustine for use in combination with radiation therapy in the treatment of solid tumorsSara Rockwell, Yanfeng Liu, Helen A Seow, et al.
Pageof 4